Table 3.
The tolerability of febuxostat treatment in patients (n = 78) with gout and hyperuricaemia treated with 80 mg febuxostat once daily for 24 weeks.
| n | Patients that did not complete treatment | Patients that had effectivetreatmenta | Patients that had ineffectivetreatmenta | |
|---|---|---|---|---|
| Number of patients | 78 | 17 (21.79) | 34 (43.59) | 27 (34.62) |
| Side-effects | 38 (48.72) | 11 (14.10) | 14 (17.95) | 13 (16.67) |
| Liver dysfunction | 28 (35.90) | 10 (12.82) | 10 (12.82) | 8 (10.26) |
| Leukocytosis | 4 (5.13) | 2 (2.56) | 1 (1.28) | 1 (1.28) |
| Polycythaemia | 2 (2.56) | 1 (1.28) | 1 (1.28) | |
| Diarrhoea | 1 (1.28) | 1 (1.28) | ||
| Headache | 1 (1.28) | 1 (1.28) | ||
| Nausea | 1 (1.28) | 1 (1.28) | ||
| Rash | 1 (1.28) | 1 (1.28) | ||
| Sleep disorder | 1 (1.28) | 1 (1.28) | ||
| Thrombocytopaenia | 1 (1.28) | 1 (1.28) |
Data presented as n of patients (%).
aIf the patients completed the treatment period and the target sUA level (6.7 mg/dl) was achieved at study end then the febuxostat treatment was considered to have been effective (ET); if the sUA target was not achieved, then it was considered ineffective treatment (IET).